Harvard Business Review

MARCH 24, 2017

The onus for ethical behavior falls first to the employee. Most companies talk a good ethics game and even make their goals public. Compensation should be tied to broad-based outcomes and include things such as customer satisfaction and product knowledge, in addition to success at closing deals. Consider the case of GSK.

Ethics 8

Ethics Company Incentives Policies 8

Harvard Business Review

JUNE 9, 2017

Few issues are more foundational to driving improvements in human health than creating productive, progressive relationships between clinical medicine and the biopharmaceutical industry. “Thou shall not” is the starting point for almost all academic institutions’ conflict-of-interest policy statements. Practicing physicians.

Conflict of Interest 9

Conflict of Interest Pharmaceuticals Policies Industry 9

Harvard Business Review

JUNE 1, 2012

She certainly wouldn't disapprove of an employee seeking prescription help to become more productive. Ironically, the money isn't the issue here; the business norms associated with perceived cosmetic and aesthetic concerns are radically different from those attached to job performance and productivity. use antidepressants, as well).

Health Care 13

Health Care Ethics Pharmaceuticals Globalization 13

Harvard Business Review

MAY 29, 2013

SAP, the German software giant, announced that it hopes to hire hundreds of autistics as talented programmers and product testers. SAP''s Bangalore office saw its productivity increase after deploying autistic hires. Talk about turning a bug into a feature. Does this describe any of your better colleagues, clients and/or employees?

Competitive Advantage 8

Competitive Advantage Ethics Human Resources Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. Negative results are usually not published at all.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.

Venture Capitalist 8

Venture Capitalist Health Care Strategic Fit Pharmaceuticals 8

Harvard Business Review

APRIL 15, 2015

If you think more about industry, you might imagine a mechanical arm programmed to install parts on a production line. million industrial robots are in use or available in various industries including automotive, electronics, rubber and plastics, cosmetics, pharmaceutical, and food and beverage. By 2003, there were 800,000.

Definition 8

Definition Ethics Industry Automotive 8

Harvard Business Review

NOVEMBER 5, 2015

As a child I felt no particular interest in pharmaceuticals, telecommunications, computers, oil and gas, health and beauty aids, medical devices, airlines, or shipbuilding, all of which I’ve simulated or war-gamed. I wonder what makes people market products that they know cause addiction and death. Then they grow up.

Career 8

Career Seminar Self-aware Telecommunications 8

Harvard Business Review

JULY 14, 2017

Pharmaceutical company Lilly has said , “Many tragic world events have shaken our employees, making it difficult for them to bring their full selves to work. The Center says that civility in its workplace builds stronger, more productive teams that deliver the highest-quality health care to patients. Take ownership of civility.

Diversity 9

Diversity Politics Survey Incubator 9

Harvard Business Review

OCTOBER 13, 2014

When pharmaceutical companies conduct clinical trials to test the safety and efficacy of their drugs as part of the process for obtaining regulatory approval, some patients receive the drug and others some standard existing treatment or a sugar pill (placebo). Take the issue of productivity.

Flextime 10

Flextime Call Center Human Resources CRM 10

Harvard Business Review

SEPTEMBER 15, 2014

Now more than ever , businesses are reaching beyond the boundaries of their organizations, tapping experts, customers, and, more broadly, “the crowd” to build new products, services, and other solutions. But as corporate leaders join this trend, they should be mindful of the two types of networks.

Gilbert 9

Gilbert Participative Cooper Network Economy 9

Harvard Business Review

JANUARY 15, 2013

Business will move the great masses of humanity forward with advancements in pharmaceuticals, materials, process, and technology — but it will almost always leave 10% behind. This we call ethics. So the voices of our great causes are all but silenced, and consumer products get lopsided access to our attention, 24/7.

Learning Curve 9

Learning Curve Advertising Pharmaceuticals GDP 9

Harvard Business Review

NOVEMBER 28, 2017

One of your executives comes to you with a proposal: she wants to lower the quality of service at the restaurants, reduce product safety standards, use deceptive marketing practices, lower employee pay, and adopt worse environmental practices. Imagine you’re the CEO of a casual dining chain. Our research. But these effects were limited.

Company 8

Company Short-term Long-term Price 8

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 8

Finance Banking Press Release Pharmaceuticals 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1% However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8